Sonio, the MedTech company specializing in women’s and children’s health, has announced the official approval by the French Ministry of the Economy and Finance of the acquisition of 100% of shares by Samsung Medison.
Established in 2020 to enhance women and children’s health globally through medical advancements, Sonio has developed IT solutions and AI assistant features for obstetrics and gynecology ultrasound that assist medical professionals in the evaluation and documentation of ultrasound exams. It is based in Paris, France and has an office in New York, New York.
Samsung Medison, an affiliate of Samsung Electronics, is a global medical equipment company founded in 1985. It is based in Seoul, South Korea.
The acquisition, which follows a share purchase agreement between the two companies made in May 2024, is being seen as a part of Samsung Medison’s push to enhance its AI-powered healthcare solution business.
“Alongside Samsung Medison, we are excited to make significant strides in the maternal care industry. In addition, Sonio plans to continue to advance medical reporting technology and diagnostic software globally, including for underserved areas in healthcare” says Cecile Brosset, Chief Executive Officer of Sonio.
Samsung Medison CEO Kyu Tae Yoo said: “With the workforce shortages affecting the global healthcare industry, the real-time ultrasound exam guidance and quality assurance developed by Sonio is becoming more relevant to ensure high quality care. We look forward to combining Sonio’s and Samsung’s advanced engineering to enhance our ultrasound roadmap and introduce next generation AI technologies to the market. We will focus on innovations designed to enhance exam quality, efficiency, and ultimately improve patient care.”
According to data captured in the LevinPro HC database, there have been 62 transactions announced in the Medical Devices sector so far during 2024. There were 113 Medical Devices deals announced during 2023, and 124 announced during 2022.
